Capricor Therapeutics Inc (NASDAQ:CAPR) Receives $24.67 Average Price Target from Analysts

Capricor Therapeutics Inc (NASDAQ:CAPR) has been assigned an average rating of “Buy” from the six brokerages that are currently covering the firm, MarketBeat reports. Six investment analysts have rated the stock with a buy recommendation. The average 1 year price target among analysts that have covered the stock in the last year is $24.67.

Several analysts have recently weighed in on the company. Maxim Group lifted their target price on Capricor Therapeutics from $12.00 to $25.00 and gave the stock a “buy” rating in a research report on Wednesday, September 25th. Oppenheimer reissued an “outperform” rating and issued a $15.00 price objective on shares of Capricor Therapeutics in a research report on Monday, September 23rd. Piper Sandler assumed coverage on shares of Capricor Therapeutics in a research report on Monday, October 21st. They set an “overweight” rating and a $35.00 target price on the stock. HC Wainwright reiterated a “buy” rating and issued a $40.00 price target on shares of Capricor Therapeutics in a report on Wednesday, October 9th. Finally, Cantor Fitzgerald restated an “overweight” rating and set a $8.00 price objective on shares of Capricor Therapeutics in a report on Friday, September 20th.

Insider Buying and Selling

In related news, major shareholder Shinyaku Co Ltd Nippon purchased 2,798,507 shares of the business’s stock in a transaction dated Friday, September 20th. The shares were acquired at an average cost of $5.36 per share, for a total transaction of $14,999,997.52. Following the acquisition, the insider now owns 7,090,351 shares of the company’s stock, valued at $38,004,281.36. The trade was a 0.00 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 12.00% of the stock is currently owned by insiders.

Institutional Trading of Capricor Therapeutics

A number of institutional investors have recently modified their holdings of the company. Vanguard Group Inc. lifted its position in Capricor Therapeutics by 17.2% during the first quarter. Vanguard Group Inc. now owns 1,365,903 shares of the biotechnology company’s stock valued at $9,274,000 after acquiring an additional 200,499 shares during the last quarter. Marshall Wace LLP purchased a new stake in shares of Capricor Therapeutics during the 2nd quarter valued at $426,000. Renaissance Technologies LLC boosted its position in shares of Capricor Therapeutics by 158.7% in the 2nd quarter. Renaissance Technologies LLC now owns 137,500 shares of the biotechnology company’s stock worth $656,000 after purchasing an additional 84,350 shares in the last quarter. Rhumbline Advisers purchased a new position in Capricor Therapeutics during the 2nd quarter worth $147,000. Finally, Oppenheimer & Co. Inc. grew its stake in Capricor Therapeutics by 25.2% during the 3rd quarter. Oppenheimer & Co. Inc. now owns 68,408 shares of the biotechnology company’s stock worth $1,040,000 after buying an additional 13,762 shares during the last quarter. 21.68% of the stock is currently owned by institutional investors.

Capricor Therapeutics Price Performance

Capricor Therapeutics stock opened at $19.70 on Wednesday. The firm has a market capitalization of $894.58 million, a P/E ratio of -21.18 and a beta of 4.00. Capricor Therapeutics has a 1-year low of $2.68 and a 1-year high of $23.40. The company’s 50-day moving average is $13.81 and its 200 day moving average is $8.00.

Capricor Therapeutics (NASDAQ:CAPR) last issued its quarterly earnings results on Wednesday, August 7th. The biotechnology company reported ($0.35) earnings per share for the quarter, missing the consensus estimate of ($0.32) by ($0.03). Capricor Therapeutics had a negative return on equity of 220.27% and a negative net margin of 102.93%. The business had revenue of $3.97 million during the quarter, compared to analysts’ expectations of $4.51 million. Research analysts anticipate that Capricor Therapeutics will post -1.17 earnings per share for the current fiscal year.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.